1. Home
  2. JBLU vs DFTX Comparison

JBLU vs DFTX Comparison

Compare JBLU & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$5.00

Market Cap

1.8B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$24.75

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JBLU
DFTX
Founded
1998
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
JBLU
DFTX
Price
$5.00
$24.75
Analyst Decision
Sell
Strong Buy
Analyst Count
13
8
Target Price
$4.91
$38.50
AVG Volume (30 Days)
23.9M
2.0M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
N/A
Revenue
$9,062,000,000.00
N/A
Revenue This Year
$12.11
N/A
Revenue Next Year
$6.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$14.62
52 Week High
$6.46
$26.25

Technical Indicators

Market Signals
Indicator
JBLU
DFTX
Relative Strength Index (RSI) 51.75 61.13
Support Level $4.90 $16.37
Resistance Level $5.15 $25.71
Average True Range (ATR) 0.24 1.48
MACD -0.01 0.06
Stochastic Oscillator 43.90 84.73

Price Performance

Historical Comparison
JBLU
DFTX

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: